SCHEMBL305210

SCHEMBL305210

CCC(C(=O)O)=C(C(=O)O)C(C)C.[Na].[Na]

nearest known ligand 0.36

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.36
GRIA4 P48058 1/20 0.36
GRIK3 Q13003 1/20 0.36
GRIK5 Q16478 1/20 0.36
FFAR3 O14843 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10193601 0.98 GRIK1 (0.38) GRIK1GRIA4GRIK3GRIK5FFAR3
SCHEMBL3516778 0.98 GRIK1 (0.38) GRIK1GRIA4GRIK3GRIK5FFAR3
SCHEMBL3516773 0.98 GRIK1 (0.38) GRIK1GRIA4GRIK3GRIK5FFAR3
SCHEMBL305208 0.95 GRIK1 (0.36) GRIK1GRIA4GRIK3GRIK5FFAR3
Dimethylamine SCHEMBL3517020 0.91 GRIK1 (0.34) GRIK1GRIA4GRIK3GRIK5FFAR3
SCHEMBL305161 0.85 GRIK1 (0.33) GRIK1GRIA4GRIK3GRIK5FFAR3
SCHEMBL5798580 0.83 TP53 (0.41) GRIK1GRIA4GRIK3GRIK5FFAR3
SCHEMBL5455564 0.83 TP53 (0.41) GRIK1GRIA4GRIK3GRIK5FFAR3
SCHEMBL305159 0.80 FFAR3 (0.31) FFAR3
SCHEMBL15751550 0.80 GRIK1 (0.33) GRIK1GRIA4GRIK3GRIK5FFAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
US-9260375-B2 Metallo-β-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2016-02-16 US disclosed
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS CHIKAUCHI KEN (JP) 2012-03-22 US disclosed
US-8093294-B2 Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2012-01-10 US disclosed
EP-1941873-A1 METALLO-BETA-LACTAMASE INHIBITOR MEIJI SEIKA KAISHA LTD. (JP) 2008-07-09 EP disclosed
US-20080090825-A1 Metallo-beta-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090825-A1 Metallo-beta-lactamase inhibitors ME1, MGAM, GAA GRIK1 2255/4885GRIA4 1947/4885GRIK3 3671/4885
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS ME1, MGAM, GAA GRIK1 2255/4885GRIA4 1947/4885GRIK3 3671/4885
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS ME1, MGAM, MANBA GRIK1 2469/4885GRIA4 2039/4885GRIK3 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.